Evidence map›Paper›PMID 40128033›Full record

Observational studyMedicine2025

Dynamic evaluation of postoperative survival in pancreatic ductal adenocarcinoma.

Bo-Wen Zheng, Xin-Yu Yang, Jun Zheng, Ru-Cheng Yao

Abstract readObservational Study
In one paragraph

Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bo-Wen ZhengDepartment of Hepato-Pancreato-Biliary Surgery, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China.
Xin-Yu YangDepartment of Hepato-Pancreato-Biliary Surgery, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China.
Jun ZhengDepartment of Hepato-Pancreato-Biliary Surgery, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China.ORCID 0009-0007-0601-7865
Ru-Cheng YaoDepartment of Hepato-Pancreato-Biliary Surgery, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China.

Funding

Health Commission of Hubei Province scientific research project WJ2021M067
6 · The paper itself

Abstract

The pancreatic ductal adenocarcinoma has a high degree of malignancy, and traditional prognostic assessment methods have limited evaluative capacity. This study is based on the Kallikrein-related peptidase 7 (KLK7) expression and uses conditional survival algorithms to perform dynamic survival assessments of patients. The Cox proportional hazards model was employed for identifying and adjusting for potential confounders. The Kaplan-Meier technique was utilized to estimate the overall survival rate. The computation of the likelihood of patients surviving an additional year after X years of survival was achieved using the equation CS1 = OS(X + 1)/OS(X). A subgroup analysis based on CS1 was conducted for each individual risk factor. A total of 243 eligible patients were included in the study. Conditioned survival (CS) refers to the years a patient has already survived and the predicted years they are likely to survive in the future, while conducting a time-varying analysis of the factors influencing prognosis. The survival probability assessed by CS1 increased year by year, with the 1-, 2-, and 3-year survival rates rising from 50.4% to 91.2%. In contrast, the actuarial overall survival (OS) decreased from 81.9% at 1 year to 38.6% at 3 years post-surgery. The results of the conditional analysis indicate that patients who survive longer within a certain timeframe have better survival expectations in the future. Adverse factors, including KLK7, have a decreasing impact on survival over time. Conditional survival analysis based on KLK7 can provide more accurate survival predictions for patients who has identified KLK7.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAdultAgedFemaleHumansKallikreinsKaplan-Meier EstimateMaleMiddle AgedPostoperative PeriodPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSurvival RateKallikreins

Identifiers

PMID40128033
PMCPMC11936588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.